CHARLES RIVER LABORATORIES INTERNA stock forecast: up to 205.06 USD CRL stock price prognosis


Forecast for Fri 26 May 2023 price 209.78

CHARLES RIVER LABORATORIES INTERNA stock price forecast for further price development up to 1.61% (time horizon: 1 day) and price target of 205.06 USD. Positive news sentiment. Short-term (time horizon: 2 weeks) CHARLES RIVER LABORATORIES INTERNA share price prediction for 2023-05-26 with daily closed price projections

Key Facts

Symbol CRL 

ISIN US1598641074 

CUSIP 159864107

Currency USD

Category Services-Commercial Physical & Biological Research

Forecast price change %

News sentiment (0.90)

News <--> Close correlation for next day influence (-0.19)

Finance numbers

Revenue 3,041,440,000.0

Earnings per share 7.38

On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

001-15943 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ( Our Internet site is The development of new drugs requires a steadily increasing investment of time and money. Research Animal Diagnostic Services. We recently launched a suite of products focused on sterility testing. Sterility testing is required prior to the release of sterile injectable products. In 2020, we launched the Celsis Complete™ and Celsis Advantage™ services. We are the global leader for the supply of SPF fertile chicken eggs and chickens. Pharmaceutical Manufacturing Support Portfolio. Flexible and Customized Environment to Provide the Right Solutions. Our clients' R&D needs continue to evolve. We also promote a healthy and safe workplace for our employees. Joseph W. LaPlume, age 47, joined us in 2005 as Senior Corporate Counsel. You should understand that it is not possible to predict or identify all such factors. Some of the same risks exist when we decide to sell a business, site or product line. Negative attention from special interest groups may impair our business. Our clients include researchers at pharmaceutical and biotechnology companies. This could result in a decrease in overall revenue and profits. The industries in which we operate are highly competitive. This could harm our reputation, our prospects for future work and our operating results. We are required to comply with the data privacy and security laws in many jurisdictions. We depend on the availability of, and good relations with, our team members. Such an impairment charge could materially and adversely affect our operating results. PropertiesWe own or lease the land and buildings where we have facilities. We own large Manufacturing facilities in the U.S., Ireland and China. Accordingly, we have and expect to continue to increase inventory and supplies in 2021. The proposed transaction is expected to close by the end of the first quarter of 2021. The acquisition was funded through available cash. The purchase price for MPI Research was $829.7 million in cash. Contracts with customers may contain multiple performance obligations. Revenue is recorded proportionally as costs are incurred. Our accounting for the elements of U.S. Tax Reform is complete. In fiscal 2020 we adopted ASU 2017-04, "Simplifying the Test for Goodwill Impairment." The increase to operating income was due primarily to the increase in revenue. These proceeds and payments are presented as gross financing activities. Purchase obligations exclude agreements that are cancellable at any time without penalty. Intercompany balances and transactions are eliminated in consolidation. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. Actual results may differ from these estimates under different assumptions or conditions. The observability of inputs may change for certain assets or liabilities. This condition could cause an asset or liability to be reclassified between levels. Inventories are stated at the lower of cost or net realizable value. Standard costs are trued-up to reflect actual cost. The Company revalues these contingent consideration obligations each reporting period. This determination is reassessed if the terms of the contract are changed. Generally, the Company does not extend payment terms beyond one year. Income taxes are accounted for under the liability method. The Company accounts for treasury stock transactions under the cost method. Thus, the

Summerized Form 10-K with GPT-2
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 60.76/100
    • Not in ideal financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.
    • Stock price is under book price value.

Institutional ownership list is based on filling form information

Holding name Date Amount
American Portfolios Advisors 2019-12-31 1597
American Portfolios Advisors 2022-06-30 1695
American Portfolios Advisors 2021-12-31 3493
Neo Ivy Capital Management 2022-12-31 2136
American Portfolios Advisors 2022-03-31 2827

Fund ownership list is based on filling form information

Fund name Date Amount Profile
SPDR SERIES TRUST 2022-12-31 1719 Long
SPDR SERIES TRUST 2022-12-31 16120 Long
SPDR SERIES TRUST 2022-12-31 1356 Long
SPDR SERIES TRUST 2022-12-31 315 Long


CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1221496 Massaro George 2022-05-09 SALE Accept Accept Accept Accept
1732091 Girshick Birgit 2023-02-16 SALE Accept Accept Accept Accept
1767215 Laplume Joseph W 2022-12-01 SALE Accept Accept Accept Accept
1543779 Knell Michael Gunnar 2022-11-16 SALE Accept Accept Accept Accept
1952784 Parisotto Shannon M 2023-02-16 SALE Reject Reject Reject Reject

Bollinger Bollinger Bands for CHARLES RIVER LABORATORIES INTERNA can provide the information where the market is moving based on price information.

CHARLES RIVER LABORATORIES INTERNA Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.

Converting prices to returns CHARLES RIVER LABORATORIES INTERNA.

On-Balance Volume information for CHARLES RIVER LABORATORIES INTERNA. On-Balance Volume information can be an indicator for bullish or bearish outcome.

Accumulation / Distribution (A/D) indicator information for CHARLES RIVER LABORATORIES INTERNA. The indicator identify divergences between price and volume flow.

Aroon Oscillator information for CHARLES RIVER LABORATORIES INTERNA. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.

Average Directional Index (ADX) information for CHARLES RIVER LABORATORIES INTERNA. The index can be used to identify the strengh of a trend.

Moving Average Convergence Divergence (MACD) for CHARLES RIVER LABORATORIES INTERNA. The indicator helps to predict trend direction and the momentum of the trend.

Stochastic Oscillator as momentum indicator for CHARLES RIVER LABORATORIES INTERNA. The indicator is useful for identifying overbought and oversold levels.

Relative Strength Index (RSI) for CHARLES RIVER LABORATORIES INTERNA. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].

52W High 52W Low Market Cap

Similar shares



Figure below show the stock predictions.
Date Closing price Prediction was updated
2023-04-27 205.06 2023-04-01 02:34
2023-04-28 205.15 2023-04-01 02:34
2023-05-01 205.38 2023-04-01 02:34
2023-05-02 205.57 2023-04-01 02:34
2023-05-08 206.61 2023-04-01 02:34
2023-05-09 206.80 2023-04-01 02:34
2023-05-10 207.08 2023-04-01 02:34
2023-05-03 205.89 2023-04-01 02:34
2023-05-04 206.06 2023-04-01 02:34
2023-05-05 206.37 2023-04-01 02:34
2023-05-11 207.27 2023-04-01 02:34
2023-05-12 207.54 2023-04-01 02:34
2023-05-17 208.21 2023-04-01 02:34
2023-05-18 208.47 2023-04-01 02:34
2023-05-19 208.67 2023-04-01 02:34
2023-05-15 207.75 2023-04-01 02:34
2023-05-16 208.02 2023-04-01 02:34
2023-05-22 208.89 2023-04-01 02:34
2023-05-23 209.12 2023-04-01 02:34
2023-05-24 209.33 2023-04-01 02:34
2023-05-26 209.78 2023-04-01 02:34
2023-05-25 209.57 2023-04-01 02:34
2023-04-03 202.29 2023-04-01 02:34
2023-04-04 201.78 2023-04-01 02:34
2023-04-05 201.53 2023-04-01 02:34
2023-04-06 201.13 2023-04-01 02:34
2023-04-07 201.38 2023-04-01 02:34
2023-04-10 200.60 2023-04-01 02:34
2023-04-11 201.73 2023-04-01 02:34
2023-04-12 202.14 2023-04-01 02:34
2023-04-13 202.03 2023-04-01 02:34
2023-04-14 202.67 2023-04-01 02:34
2023-04-17 202.65 2023-04-01 02:34
2023-04-18 202.98 2023-04-01 02:34
2023-04-19 203.09 2023-04-01 02:34
2023-04-20 203.76 2023-04-01 02:34
2023-04-21 203.76 2023-04-01 02:34
2023-04-24 204.50 2023-04-01 02:34
2023-04-25 204.56 2023-04-01 02:34
2023-04-26 204.83 2023-04-01 02:34

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.